| pubmed-article:16125638 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0473169 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0025815 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0856825 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0717758 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:16125638 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:16125638 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:16125638 | pubmed:dateCreated | 2005-8-29 | lld:pubmed |
| pubmed-article:16125638 | pubmed:abstractText | Clinical and preclinical data indicate that tumor necrosis factor (TNF)-alpha is an important mediator of acute graft-versus-host disease (aGVHD) after allogeneic bone marrow transplantation. We completed a study using etanercept, a fusion protein capable of neutralizing TNF-alpha, for the initial treatment of aGVHD. Etanercept (25 mg subcutaneously) was administered twice weekly for 16 doses, along with methylprednisolone (2 mg/kg) and tacrolimus for biopsy-proven aGVHD. Twenty patients with a median age of 47 years (range, 8-63 years) were enrolled. Fourteen patients with grade II aGVHD (11 family donors and 3 unrelated donors) and 6 patients with grade III aGVHD (3 family donors and 3 unrelated donors) were treated. Twelve patients completed 16 doses of therapy, and 8 received 5 to 15 doses. Reasons for not completing all doses of etanercept included progression of aGVHD (n = 4), relapsed leukemia (n = 2), progression of pulmonary and central nervous system lesions (n = 1), and perforated duodenal ulcer (n = 1). Fifteen (75%) of 20 patients had complete resolution of aGVHD within 4 weeks of therapy. Increasing levels of soluble TNF receptor 1 plasma concentration during the first 4 weeks of therapy indicated progression of aGVHD in 5 patients. In contrast, for 15 responding patients, soluble TNF receptor 1 plasma concentration levels returned to baseline. These data demonstrate the feasibility of using cytokine blockade in the early treatment of aGVHD. | lld:pubmed |
| pubmed-article:16125638 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16125638 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16125638 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16125638 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16125638 | pubmed:issn | 1083-8791 | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:RoenP BPB | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:BraunThomasT | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:LevineJohn... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:FerraraJames... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:BeckerMichael... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:CookeKenneth... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:HutchinsonRay... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:YanikGregoryG | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:UbertiJoseph... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:AyashLoisL | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:ReynoldsChris... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:Ratanatharath... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:SilverSamuelS | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:WhitfieldJoel... | lld:pubmed |
| pubmed-article:16125638 | pubmed:author | pubmed-author:JonesDawnD | lld:pubmed |
| pubmed-article:16125638 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16125638 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:16125638 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16125638 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16125638 | pubmed:pagination | 680-7 | lld:pubmed |
| pubmed-article:16125638 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:meshHeading | pubmed-meshheading:16125638... | lld:pubmed |
| pubmed-article:16125638 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16125638 | pubmed:articleTitle | Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. | lld:pubmed |
| pubmed-article:16125638 | pubmed:affiliation | Department of Internal Medicine, Blood and Marrow Stem Cell Transplantation Program, University of Michigan, Ann Arbor, USA. ubertij@karmanos.org | lld:pubmed |
| pubmed-article:16125638 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16125638 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16125638 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16125638 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16125638 | lld:pubmed |
